COVID-19 vaccine: Johnson & Johnson's single dose vaccine approved in India for emergency use

Johnson & Johnson single-dose vaccine has been approved in India. With this, India now has 5 approved COVID-19 vaccines- COVAXIN, Covishield, Sputnik V, Johnson & Johnson, and Moderna. 

Created On: Aug 7, 2021 13:41 IST
Johnson & Johnson Vaccine
Johnson & Johnson Vaccine

Johnson & Johnson's single-dose COVID-19 vaccine has been given approval for emergency use in India. With this, India now has 5 approved COVID-19 vaccines- COVAXIN, Covishield, Sputnik V, Johnson & Johnson, and Moderna. 

The global healthcare major Johnson & Johnson announced on August 6, 2021, that it has applied for the Emergency Use Authorization (EUA) of its single-dose Coronavirus vaccine in India.

Earlier, the company had mentioned that it remained committed to bringing its single-dose vaccine to India and also looks forward to the ongoing discussions with the Government of India.

Johnson& Johnson in an official statement stated that the company looks forward to concluding its discussion with the Indian Government in order to accelerate the availability of its single-dose vaccine to help the pandemic.

Johnson & Johnson collaborates with Biological E:

A spokesperson of Johnson & Johnson said in a statement that on August 5, 2021, the company has applied for the Emergency Use Authorization of its single-dose COVID-19 vaccine to the Indian Government.

The statement further added that this will be an important milestone that will pave the way for bringing the company’s single-dose vaccine to the people of India and the rest of the world, through a collaboration with Hyderabad-based Biological E Limited.

Biological E will be a significant part of Johnson & Johnson’s global supply chain network, helping to supply the COVID-19 vaccine through the extensive collaborations and partnerships that the company has with governments, health authorities, and organisations such as the COVAX facility and GAVI.

EUA submission in India:

The Emergency Use Authorization submission is based on the topline efficacy and safety data from the phase 3 ENSEMBLE clinical trial. It demonstrated that the company’s single-shot vaccine was 85% effective in preventing severe disease across all the regions studied.

The trial showed the protection against the COVID-19 related deaths and hospitalization, beginning 28 days after the vaccination.

COVID-19 cases in India:

According to the Health Ministry on August 6, 2021, the country recorded 44,643 new COVID-19 cases, taking the total tally to 3,18,56,757, while the active COVID cases registered an increase for the third consecutive day.

Take Weekly Tests on app for exam prep and compete with others. Download Current Affairs and GK app

एग्जाम की तैयारी के लिए ऐप पर वीकली टेस्ट लें और दूसरों के साथ प्रतिस्पर्धा करें। डाउनलोड करें करेंट अफेयर्स ऐप

AndroidIOS

Related Stories

Monthly Current Affairs PDF

  • Current Affairs PDF November 2021
  • Current Affairs PDF October 2021
  • Current Affairs PDF September 2021
  • Current Affairs PDF August 2021
  • Current Affairs PDF July 2021
  • Current Affairs PDF June 2021
View all

Monthly Current Affairs Quiz PDF

  • Current Affairs Quiz PDF November 2021
  • Current Affairs Quiz PDF October 2021
  • Current Affairs Quiz PDF September 2021
  • Current Affairs Quiz PDF August 2021
  • Current Affairs Quiz PDF July 2021
  • Current Affairs Quiz PDF June 2021
View all
Comment (0)

Post Comment

2 + 5 =
Post
Disclaimer: Comments will be moderated by Jagranjosh editorial team. Comments that are abusive, personal, incendiary or irrelevant will not be published. Please use a genuine email ID and provide your name, to avoid rejection.
    Whatsapp IconGet Updates

    Just Now